New pill targets 'Undruggable' cancer driver in desperate patients
NCT ID NCT04678648
Summary
This early-stage trial is testing a new oral drug called RSC-1255 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how well the drug is tolerated, both alone and combined with another medication. The study focuses on cancers with specific genetic changes (RAS mutations), which are common in lung, colon, pancreatic cancer, and glioblastoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sarah Cannon, SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon, SCRI Oncology Partners - Health One
RECRUITINGDenver, Colorado, 80218, United States
-
University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology
RECRUITINGLos Angeles, California, 90404, United States
Conditions
Explore the condition pages connected to this study.